CAV1 and hepatocellular carcinoma: CAV1 downregulation restored lenvatinib sensitivity in HCC PDOs by suppressing FGFR4-mediated STAT3/AKT/ERK signalling, reducing IL-8 and MMP-9 mRNA, and p21 protein levels, while inducing c-PARP expression, a marker of apoptosis (Fig. 7K–M, Suppl.